MX2014002480A - Uso del compuesto organico para el tratamiento del sindrome de noonan. - Google Patents
Uso del compuesto organico para el tratamiento del sindrome de noonan.Info
- Publication number
- MX2014002480A MX2014002480A MX2014002480A MX2014002480A MX2014002480A MX 2014002480 A MX2014002480 A MX 2014002480A MX 2014002480 A MX2014002480 A MX 2014002480A MX 2014002480 A MX2014002480 A MX 2014002480A MX 2014002480 A MX2014002480 A MX 2014002480A
- Authority
- MX
- Mexico
- Prior art keywords
- noonan syndrome
- treatment
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 206010029748 Noonan syndrome Diseases 0.000 title abstract 4
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940124647 MEK inhibitor Drugs 0.000 abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El uso de un compuesto inhibidor de MEK de la Fórmula (I), como se define en la presente, o una sal farmacéuticamente aceptable del mismo para la preparación de un medicamento para el tratamiento del síndrome de Noonan, un método de tratamiento de un animal de sangre caliente, especialmente un ser humano, que tiene síndrome de Noonan, que comprende administrar al animal una cantidad terapéuticamente efectiva de un compuesto inhibidor de MEK de la Fórmula (I), como se define en la presente, o una sal farmacéuticamente aceptable del mismo; y a una composición farmacéutica y un envase comercial que comprende un compuesto de la Fórmula (I) o una sal farmacéuticamente aceptable del mismo, y un inserto de envase u otro etiquetado que incluye instrucciones para el tratamiento del síndrome de Noonan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530128P | 2011-09-01 | 2011-09-01 | |
| PCT/US2012/052750 WO2013033133A1 (en) | 2011-09-01 | 2012-08-29 | Use of organic compound for the treatment of noonan syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014002480A true MX2014002480A (es) | 2014-03-27 |
Family
ID=46826924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002480A MX2014002480A (es) | 2011-09-01 | 2012-08-29 | Uso del compuesto organico para el tratamiento del sindrome de noonan. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9034909B2 (es) |
| EP (1) | EP2750672A1 (es) |
| JP (1) | JP2014528928A (es) |
| KR (1) | KR20140068037A (es) |
| CN (1) | CN103764134A (es) |
| AU (1) | AU2012302106B2 (es) |
| BR (1) | BR112014002885A2 (es) |
| CA (1) | CA2845571A1 (es) |
| CL (1) | CL2014000496A1 (es) |
| IL (1) | IL231126A0 (es) |
| MA (1) | MA35363B1 (es) |
| MX (1) | MX2014002480A (es) |
| PH (1) | PH12014500191A1 (es) |
| RU (1) | RU2014112324A (es) |
| SG (1) | SG2014005029A (es) |
| TN (1) | TN2014000031A1 (es) |
| WO (1) | WO2013033133A1 (es) |
| ZA (1) | ZA201400460B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101665143B1 (ko) | 2007-12-19 | 2016-10-11 | 캔써 리서치 테크놀로지 리미티드 | 피리도[2,3-ｂ]피라진-8 치환 화합물 및 이의 용도 |
| AU2011209586B2 (en) | 2010-02-01 | 2016-01-21 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy |
| FI3702351T3 (fi) | 2012-10-19 | 2024-01-24 | Array Biopharma Inc | MEK-inhibiittorin käsittävä koostumus |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP6670494B2 (ja) * | 2014-10-09 | 2020-03-25 | 国立大学法人 東京大学 | 心筋細胞の製造方法、心室型心筋細胞及びその製造方法、並びにスクリーニング方法 |
| CN111646946A (zh) | 2017-11-14 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的苯并咪唑化合物及包含该化合物的组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8569301A1 (es) | 2002-03-13 | 2004-10-08 | Array Biopharma Inc | "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors" |
| US20100227778A1 (en) * | 2006-08-18 | 2010-09-09 | The Brigham And Women's Hospital, Inc. | Diagnosis and Treatment of Noonan Syndrome and Neoplastic Disorders |
| WO2009135000A2 (en) | 2008-04-30 | 2009-11-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs |
-
2012
- 2012-08-29 MX MX2014002480A patent/MX2014002480A/es unknown
- 2012-08-29 CA CA2845571A patent/CA2845571A1/en not_active Abandoned
- 2012-08-29 JP JP2014528530A patent/JP2014528928A/ja active Pending
- 2012-08-29 SG SG2014005029A patent/SG2014005029A/en unknown
- 2012-08-29 KR KR1020147005039A patent/KR20140068037A/ko not_active Withdrawn
- 2012-08-29 EP EP12756614.9A patent/EP2750672A1/en not_active Withdrawn
- 2012-08-29 RU RU2014112324/15A patent/RU2014112324A/ru not_active Application Discontinuation
- 2012-08-29 AU AU2012302106A patent/AU2012302106B2/en not_active Ceased
- 2012-08-29 CN CN201280042502.XA patent/CN103764134A/zh active Pending
- 2012-08-29 PH PH1/2014/500191A patent/PH12014500191A1/en unknown
- 2012-08-29 BR BR112014002885A patent/BR112014002885A2/pt not_active IP Right Cessation
- 2012-08-29 US US14/239,165 patent/US9034909B2/en not_active Expired - Fee Related
- 2012-08-29 WO PCT/US2012/052750 patent/WO2013033133A1/en not_active Ceased
-
2014
- 2014-01-21 TN TNP2014000031A patent/TN2014000031A1/en unknown
- 2014-01-21 ZA ZA2014/00460A patent/ZA201400460B/en unknown
- 2014-02-24 IL IL231126A patent/IL231126A0/en unknown
- 2014-02-28 MA MA36785A patent/MA35363B1/fr unknown
- 2014-02-28 CL CL2014000496A patent/CL2014000496A1/es unknown
-
2015
- 2015-05-12 US US14/709,607 patent/US20150320725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002885A2 (pt) | 2017-02-21 |
| JP2014528928A (ja) | 2014-10-30 |
| MA35363B1 (fr) | 2014-08-01 |
| EP2750672A1 (en) | 2014-07-09 |
| US9034909B2 (en) | 2015-05-19 |
| SG2014005029A (en) | 2014-03-28 |
| KR20140068037A (ko) | 2014-06-05 |
| NZ620542A (en) | 2014-12-24 |
| US20150320725A1 (en) | 2015-11-12 |
| TN2014000031A1 (en) | 2015-07-01 |
| WO2013033133A1 (en) | 2013-03-07 |
| ZA201400460B (en) | 2014-11-26 |
| US20140200249A1 (en) | 2014-07-17 |
| CA2845571A1 (en) | 2013-03-07 |
| AU2012302106A1 (en) | 2014-03-06 |
| CN103764134A (zh) | 2014-04-30 |
| RU2014112324A (ru) | 2015-10-10 |
| CL2014000496A1 (es) | 2014-09-26 |
| PH12014500191A1 (en) | 2014-03-03 |
| AU2012302106B2 (en) | 2015-04-09 |
| IL231126A0 (en) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013006846A (es) | Inhibidores de la replicacion de los virus de la influenza. | |
| PH12014500257A1 (en) | Inhibitors of influenza viruses replication | |
| WO2012083122A8 (en) | Inhibitors of influenza viruses replication | |
| SG10201405826RA (en) | Inhibitors of influenza viruses replication | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| MX2014008021A (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MD4602B1 (ro) | Inhibitori ai virusului hepatic C | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| PH12014500065A1 (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| MX2014003701A (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
| EA201390345A1 (ru) | Терапевтическое болеутоляющее средство | |
| RU2013148627A (ru) | Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| WO2015065628A3 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| MY199579A (en) | New use of isoquinoline derivatives for diabetic wound healing | |
| PH12013501638A1 (en) | (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment | |
| TN2009000427A1 (en) | Use of hdac inhibitors for the treatment of gastrointestinal cancers | |
| UA110849C2 (uk) | Сполуки для лікування та профілактики респіраторного синцитіального вірусного захворювання | |
| UA42947U (ru) | Способ экспериментальной коррекции травматических повреждений роговицы |